NASDAQ : MNKD
MannKind Corporation — Key statistics
Healthcare · Biotechnology · United States
Last price 3.5 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.13B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.13B |
| Enterprise Value | 1.45B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 321.54M |
| Shares Outstanding | 321.54M |
| Shares Change (YoY) | -7.89% |
| Shares Change (QoQ) | +0.30% |
| Owned by Insiders (%) | 1.85% |
| Owned by Institutions (%) | 52.12% |
| Float | 297.60M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | 45.11 |
| PS Ratio | 2.86 |
| Forward PS | 2.29 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 3.68 |
| EV / EBITDA | 74.13 |
| EV / EBIT | 199.35 |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.72 |
| Quick Ratio | 1.29 |
| Debt / Equity | n/a |
| Debt / EBITDA | 18.76 |
| Debt / FCF | n/a |
| Interest Coverage | 0.15 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 0.79% |
| Return on Invested Capital (ROIC) | 1.21% |
| Return on Capital Employed (ROCE) | 1.23% |
| Weighted Average Cost of Capital (WACC) | 9.82% |
| Revenue Per Employee | $664,914 |
| Profits Per Employee | -$73,672 |
| Employee Count | 592 |
| Asset Turnover | 0.69 |
| Inventory Turnover | 2.66 |
Taxes
| Measure | Value |
|---|
| Income Tax | -5.04M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.08 |
| 52-Week Price Change | -36.82% |
| 50-Day Moving Average | 3.58 |
| 200-Day Moving Average | 3.73 |
| Relative Strength Index (RSI) | 55.60 |
| Average Volume (20 Days) | 3,466,039 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 25.48M |
| Short Previous Month | 26.16M |
| Short % of Shares Out | 7.92% |
| Short % of Float | 8.56% |
| Short Ratio (days to cover) | 4.69 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 393.63M |
| Gross Profit | 296.74M |
| Operating Income | 7.26M |
| Pretax Income | -48.65M |
| Net Income | -43.61M |
| EBITDA | 19.54M |
| EBIT | 7.26M |
| Loss Per Share | -$0.16 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 111.13M |
| Total Debt | 433.83M |
| Net Cash | -322.70M |
| Net Cash Per Share | -$1.00 |
| Equity (Book Value) | -67.20M |
| Book Value Per Share | -0.22 |
| Working Capital | 102.81M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -8.05M |
| Capital Expenditures | -10.08M |
| Depreciation & Amortization | 12.27M |
| Net Borrowing | 288.61M |
| Free Cash Flow | -18.14M |
| FCF Per Share | -$0.06 |
Margins
| Measure | Value |
|---|
| Gross Margin | 75.39% |
| Operating Margin | 1.85% |
| Pretax Margin | -12.36% |
| Profit Margin | -11.08% |
| EBITDA Margin | 4.96% |
| EBIT Margin | 1.85% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 7.89% |
| Shareholder Yield | 7.89% |
| Earnings Yield | -4.50% |
| FCF Yield | -1.61% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $8.08 |
| Price Target Difference | 130.94% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | 14.08% |
| EPS Growth Forecast (3Y) | -14.20% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Mar 3, 2017 |
| Split Type | Reverse |
| Split Ratio | 1:5 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -4.42 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |